Aflibercept in Patients With Pigment Epithelial Detachments (PED)

Pigment Epithelial Detachment Clinical Trial

Official title:
Intravitreal Aflibercept in Patients With Retinal Pigment Epithelial Detachment (PED) Secondary to Age Related Macular Degeneration (AMD)

Status Completed

Clinical Trial Summary

Uncontrolled single site non randomized non interventional study to determine the safety and efficacy of intravitreal injections of Aflibercept in patients with recent vision loss due to retinal pigment epithelial detachment secondary to AMD

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03370380
Study type	Observational
Source	University Hospital Muenster
Contact
Status	Completed
Phase
Start date	April 17, 2015
Completion date	April 23, 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00590694` - Lucentis for Age-related Macular Degeneration Pigment Epithelial Detachments	Phase 2/Phase 3
Terminated	`NCT01334255` - iSONEP to Treat Persistent Pigment Epithelial Detachment (PED) in Subjects With Exudative Age-Related Macular Degeneration (AMD) or Polypoidal Choroidal Vasculopathy (PCV)	Phase 1
Completed	`NCT00976222` - Intravitreal Ranibizumab in Retinal Pigment Epithelial Detachments	Phase 4
Completed	`NCT00841581` - Lucentis to Treat Pigment Epithelial Detachment	Phase 2
Active, not recruiting	`NCT01670162` - On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD)	Phase 4